{"transactions":[{"id":1016812,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":155262,"price":17.75,"value":2755900.5,"ownership":{"direct":false,"nature":"By Pontifax Late Stage Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016811,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1226412,"price":17.75,"value":21768813.0,"ownership":{"direct":false,"nature":"By Pontifax (China) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016810,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1121045,"price":17.75,"value":19898548.75,"ownership":{"direct":false,"nature":"By Pontifax (Cayman) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016809,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":2284612,"price":17.75,"value":40551863.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1119209,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T16:15:17.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10500,"derivative":{"exercise_price":14.82,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001415889-25-015977","document":"form4-06062025_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000141588925015977/form4-06062025_040613.xml","form_type":"4"}},{"id":1119208,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T16:15:17.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001415889-25-015977","document":"form4-06062025_040613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000141588925015977/form4-06062025_040613.xml","form_type":"4"}},{"id":1494813,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T16:15:19.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":46.31,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-015155","document":"form4-06032024_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000141588924015155/form4-06032024_040615.xml","form_type":"4"}},{"id":1861809,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:45:31.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":48.79,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-035459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919123035459/doc4.xml","form_type":"4"}},{"id":2040581,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-31T21:08:40.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":2859,"derivative":{"exercise_price":4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001104659-23-008599","document":"tm234943-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923008599/tm234943-2_4seq1.xml","form_type":"4"}},{"id":2101179,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1914},"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2101178,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1723},"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2101177,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":3539},"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2101176,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0.0001,"value":0.1914,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1226412,"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2101175,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0.0001,"value":0.1723,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1121045,"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2101174,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T16:38:39.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0.0001,"value":0.3539,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2284612,"source":{"system":"sec-edgar","filing":"0001209191-22-059051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122059051/doc4.xml","form_type":"4"}},{"id":2228486,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:24:38.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072176","document":"tm2218714-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072176/tm2218714-2_4seq1.xml","form_type":"4"}},{"id":2243780,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-03T16:27:35.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":32.95,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-22-034045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919122034045/doc4.xml","form_type":"4"}},{"id":2682402,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-03T17:31:39.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":51.48,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-21-037795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919121037795/doc4.xml","form_type":"4"}},{"id":2703641,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:46.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002612","document":"form4-05202021_040528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002612/form4-05202021_040528.xml","form_type":"4"}},{"id":2710676,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:00:45.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":592592,"price":1.35,"value":799999.2,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd., the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":616592,"source":{"system":"sec-edgar","filing":"0001104659-21-067333","document":"tm2116620d1_4s.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067333/tm2116620d1_4s.xml","form_type":"4"}},{"id":2710675,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:00:45.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1422222,"price":1.35,"value":1919999.7,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1989551,"source":{"system":"sec-edgar","filing":"0001104659-21-067333","document":"tm2116620d1_4s.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067333/tm2116620d1_4s.xml","form_type":"4"}},{"id":2710674,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:00:45.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2630487,"price":1.35,"value":3551157.45,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":3679797,"source":{"system":"sec-edgar","filing":"0001104659-21-067333","document":"tm2116620d1_4s.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067333/tm2116620d1_4s.xml","form_type":"4"}},{"id":2710673,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:00:45.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1280624,"price":1.35,"value":1728842.4,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1791470,"source":{"system":"sec-edgar","filing":"0001104659-21-067333","document":"tm2116620d1_4s.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067333/tm2116620d1_4s.xml","form_type":"4"}},{"id":2973267,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:39:39.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":6000,"price":50,"value":300000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":155262,"source":{"system":"sec-edgar","filing":"0001209191-20-059410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059410/doc4.xml","form_type":"4"}},{"id":2973266,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:39:39.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":14400,"price":50,"value":720000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1228326,"source":{"system":"sec-edgar","filing":"0001209191-20-059410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059410/doc4.xml","form_type":"4"}},{"id":2973265,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:39:39.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":12966,"price":50,"value":648300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1122768,"source":{"system":"sec-edgar","filing":"0001209191-20-059410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059410/doc4.xml","form_type":"4"}},{"id":2973264,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:39:39.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":26634,"price":50,"value":1331700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2288151,"source":{"system":"sec-edgar","filing":"0001209191-20-059410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059410/doc4.xml","form_type":"4"}},{"id":3137699,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:36.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001302","document":"form4-05222020_040521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001302/form4-05222020_040521.xml","form_type":"4"}},{"id":3177684,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":36858,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36858},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177683,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":79653,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79653},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177682,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":88460,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":88460},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177681,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":163612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":163612},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177680,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":68654,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68654},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177679,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":91538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":91538},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177678,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":82425,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":82425},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177677,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":169307,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":169307},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177676,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":737226,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737226},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177675,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":663825,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":663825},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177674,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":1363542,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1363542},"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177673,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":43750,"price":16,"value":700000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":149262,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177672,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":105000,"price":16,"value":1680000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1213926,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177671,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":94546,"price":16,"value":1512736.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1109802,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177670,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":194203,"price":16,"value":3107248.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2261517,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177669,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":36858,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":105512,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177668,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":79653,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1108926,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177667,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":88460,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1015256,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177666,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":163612,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2067314,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177665,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":68654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":68654,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177664,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":91538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1029273,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177663,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":82425,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":926796,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177662,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":169307,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1903702,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177661,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":737226,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":937735,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177660,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":663825,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":844371,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3177659,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:13:11.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":1363542,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1734395,"source":{"system":"sec-edgar","filing":"0001209191-20-024226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919120024226/doc4.xml","form_type":"4"}},{"id":3333605,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-20T20:00:11.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":10869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders."}],"balance_after":10869,"derivative":{"exercise_price":12.65,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":10869},"source":{"system":"sec-edgar","filing":"0001209191-19-061660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000120919119061660/doc4.xml","form_type":"4"}},{"id":3373051,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-13","kind":"exercise","acquired":false,"shares":5500001,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":884671},"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3373050,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-13","kind":"exercise","acquired":true,"shares":884671,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":1134671,"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3373049,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-11","kind":"purchase","acquired":true,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the \"Pontifax Entities\") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. (\"Late Stage L.P.\") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3478195,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:48:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":24000,"price":9,"value":216000.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd., the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001144204-19-032484","document":"tv524334_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032484/tv524334_form4.xml","form_type":"4"}},{"id":3478194,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:48:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":46933,"price":9,"value":422397.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":567329,"source":{"system":"sec-edgar","filing":"0001144204-19-032484","document":"tv524334_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032484/tv524334_form4.xml","form_type":"4"}},{"id":3478193,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:48:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":86806,"price":9,"value":781254.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1049310,"source":{"system":"sec-edgar","filing":"0001144204-19-032484","document":"tv524334_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032484/tv524334_form4.xml","form_type":"4"}},{"id":3478192,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:48:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":42261,"price":9,"value":380349.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":510846,"source":{"system":"sec-edgar","filing":"0001144204-19-032484","document":"tv524334_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032484/tv524334_form4.xml","form_type":"4"}},{"id":3509083,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T21:13:16.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":9.02,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000623","document":"form4-05292019_020503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000623/form4-05292019_020503.xml","form_type":"4"}},{"id":3678870,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy Common Shares)","published_at":"2019-02-04T17:22:03.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Exercise price represents the volume weighted average closing price of the Issuer's common shares on the Nasdaq Capital Market for Grant Date (as defined below) and the four (4) trading days preceding the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person is a participant in the Issuer's Incentive Plan (the \"Plan\"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the \"Grant Date\"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the \"Option Agreement\"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement."}],"balance_after":200000,"derivative":{"exercise_price":1.64,"expiration_date":"2029-01-31","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-19-001347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315219001347/ownership.xml","form_type":"4"}},{"id":3728403,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T12:10:05.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":185714,"price":1.4,"value":259999.6,"ownership":{"direct":false,"nature":"By Pontifax Late Stage Fund L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd., the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":185714,"source":{"system":"sec-edgar","filing":"0001493152-18-017647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218017647/ownership.xml","form_type":"4"}},{"id":3728402,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T12:10:05.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":331429,"price":1.4,"value":464000.6,"ownership":{"direct":false,"nature":"By Pontifax (China) IV Limited Partnership"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":943451,"source":{"system":"sec-edgar","filing":"0001493152-18-017647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218017647/ownership.xml","form_type":"4"}},{"id":3728401,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T12:10:05.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":298431,"price":1.4,"value":417803.4,"ownership":{"direct":false,"nature":"By Pontifax (Cayman) IV Limited Partnership"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV is the general partner of Cayman IV. Management 4 is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":849520,"source":{"system":"sec-edgar","filing":"0001493152-18-017647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218017647/ownership.xml","form_type":"4"}},{"id":3728400,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T12:10:05.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":612997,"price":1.4,"value":858195.8,"ownership":{"direct":false,"nature":"By Pontifax (Israel) IV Limited Partnership"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1744969,"source":{"system":"sec-edgar","filing":"0001493152-18-017647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218017647/ownership.xml","form_type":"4"}},{"id":3782794,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":627105,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV is the general partner of Cayman IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":328339},"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782793,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":696444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by China IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":328339,"derivative":{"underlying":"Common Stock","underlying_shares":364643},"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782792,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":1288116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. The Reporting Person is a Managing Partner of Management 4. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":692982,"derivative":{"underlying":"Common Stock","underlying_shares":674431},"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782791,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"purchase","acquired":true,"shares":100849,"price":10,"value":1008490.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV is the general partner of Cayman IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":1787413,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782790,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"purchase","acquired":true,"shares":112000,"price":10,"value":1120000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by China IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":1686564,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782789,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"purchase","acquired":true,"shares":207151,"price":10,"value":2071510.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. The Reporting Person is a Managing Partner of Management 4. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":1574564,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782788,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":true,"shares":328339,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV is the general partner of Cayman IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":1367413,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782787,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":true,"shares":364643,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by China IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Exchange Act or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":1039074,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3782786,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T18:27:41.000Z","date":"2018-10-23","kind":"exercise","acquired":true,"shares":674431,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. The Reporting Person is a Managing Partner of Management 4. By virtue of this relationship, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of these securities in which he has no pecuniary interest."}],"balance_after":674431,"source":{"system":"sec-edgar","filing":"0000899243-18-027480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027480/doc4.xml","form_type":"4"}},{"id":3785755,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-22T21:13:15.000Z","date":"2018-10-18","kind":"grant","acquired":true,"shares":24102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, October 18, 2018."}],"balance_after":24102,"derivative":{"exercise_price":10,"expiration_date":"2028-10-17","underlying":"Common Stock","underlying_shares":24102},"source":{"system":"sec-edgar","filing":"0000899243-18-027212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1568077/000089924318027212/doc4.xml","form_type":"4"}},{"id":3889175,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T22:08:53.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a General Partner."}],"balance_after":40000,"derivative":{"exercise_price":23.27,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-038654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118038654/doc4.xml","form_type":"4"}},{"id":3952304,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:31:01.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":93333,"price":9.75,"value":909996.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":520396,"source":{"system":"sec-edgar","filing":"0001209191-18-027105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027105/doc4.xml","form_type":"4"}},{"id":3952303,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:31:01.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":172626,"price":9.75,"value":1683103.5,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":962504,"source":{"system":"sec-edgar","filing":"0001209191-18-027105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027105/doc4.xml","form_type":"4"}},{"id":3952302,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:31:01.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":84041,"price":9.75,"value":819399.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":468585,"source":{"system":"sec-edgar","filing":"0001209191-18-027105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027105/doc4.xml","form_type":"4"}},{"id":3984111,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1600,"price":8,"value":12800.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":427063,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":3984110,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":2959,"price":8,"value":23672.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":789878,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":3984109,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1441,"price":8,"value":11528.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":384544,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":3984108,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1760,"price":7.55,"value":13288.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":425463,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":3984107,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":3255,"price":7.55,"value":24575.25,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":786919,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":3984106,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:18:27.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1585,"price":7.55,"value":11966.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":383103,"source":{"system":"sec-edgar","filing":"0001209191-18-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021395/doc4.xml","form_type":"4"}},{"id":4087381,"issuer":{"id":111039,"kind":"organization","name":"VBI Vaccines Inc/BC","symbol":"VBIV"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy Common Shares)","published_at":"2018-01-29T15:13:26.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Incentive Plan (the \"Plan\"). The board of directors of the Issuer approved the option grant on January 23, 2018 (the \"Grant Date\"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 23, 2018 (the \"Option Agreement\"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement."}],"balance_after":75000,"derivative":{"exercise_price":4.19,"expiration_date":"2028-01-23","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-18-001176","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/764195/000149315218001176/form4.xml","form_type":"4"}}]}